Business UpdateJun 9, 2026, 04:06 PM
Insight Molecular Diagnostics to Highlight GraftAssure at Transplant Congress
AI Summary
Insight Molecular Diagnostics (iMDx) will highlight its GraftAssure™ technology at the American Transplant Congress from June 20-24 in Boston. The company plans to showcase favorable third-party head-to-head data and announce the winners of a grant, co-sponsored with the American Society of Transplant Surgeons, to evaluate the economics of in-house organ rejection testing. iMDx is at a pivotal stage in commercializing GraftAssure, which includes a CLIA-certified lab-developed test and an IVD kit under FDA review, aiming to transform organ rejection monitoring with faster, more affordable in-house testing.
Key Highlights
- Insight Molecular Diagnostics to highlight GraftAssure technology at American Transplant Congress (June 20-24).
- Company will showcase favorable third-party head-to-head data for GraftAssure technology.
- iMDx to announce winners of a grant with ASTS for in-house testing economics.
- GraftAssureDx, an in vitro diagnostic (IVD) kit, is currently under FDA marketing authorization review.
- GraftAssureCore is iMDx's commercially available CLIA-certified lab-developed test.
- iMDx's assay was used in a groundbreaking 2024 NEJM study on anti-CD38 therapies.
- Company sees three paradigm shifts in organ health monitoring, including local testing.
Price Impact
More from IMDX